A high amount of belly fat, otherwise known as visceral fat, can be seen as associated with an increased risk of severe health concerns such as diabetes, cardiovascular disease, and strokes
Some patients have reported gastroparesis and ideations of self-harm
Anticipated advancements in treatment personalization and technology promise to enhance the efficacy and engagement of patients in their care, ushering in a new era of diabetes management
Important safety information Certain GLP-1 therapies such as semaglutide (the active ingredient in Ozempic, Rybelsus, and Wegovy), liraglutide (the active ingredient in Saxenda and Victoza), and tirzepatide (the active ingredient in Mounjaro and Zepbound) may increase the likelihood of developing thyroid gland tumors, including MTC, a type of thyroid cancer